(2022). Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
Programme Death Ligand 1 Expressions as a Surrogate for Determining Immunotherapy in Cervical Carcinoma Patients. 2022.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
Programme Death Ligand 1 Expressions as a Surrogate for Determining Immunotherapy in Cervical Carcinoma Patients. 2022.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.